Intra-Cellular Therapies Future Growth
Future criteria checks 5/6
Intra-Cellular Therapies is forecast to grow earnings and revenue by 68.4% and 33.2% per annum respectively while EPS is expected to grow by 67.3% per annum.
Key information
68.4%
Earnings growth rate
67.3%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 33.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 27 Oct 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,007 | 239 | 262 | 255 | 9 |
| 12/31/2024 | 672 | -37 | -24 | -26 | 11 |
| 12/31/2023 | 458 | -203 | -213 | -133 | 12 |
| 6/30/2023 | 366 | -184 | -190 | -189 | N/A |
| 3/31/2023 | 311 | -228 | -248 | -247 | N/A |
| 12/31/2022 | 250 | -256 | -271 | -270 | N/A |
| 9/30/2022 | 188 | -298 | -305 | -304 | N/A |
| 6/30/2022 | 138 | -321 | -331 | -330 | N/A |
| 3/31/2022 | 103 | -304 | -296 | -295 | N/A |
| 12/31/2021 | 84 | -284 | -260 | -260 | N/A |
| 9/30/2021 | 71 | -259 | -255 | -255 | N/A |
| 6/30/2021 | 56 | -237 | -239 | -239 | N/A |
| 3/31/2021 | 38 | -232 | -227 | -227 | N/A |
| 12/31/2020 | 23 | -227 | -230 | -230 | N/A |
| 9/30/2020 | 10 | -207 | -196 | -197 | N/A |
| 6/30/2020 | 3 | -187 | -163 | -163 | N/A |
| 3/31/2020 | 1 | -160 | -144 | -144 | N/A |
| 12/31/2019 | 0 | -148 | -129 | -128 | N/A |
| 9/30/2019 | N/A | -148 | -123 | -122 | N/A |
| 6/30/2019 | N/A | -155 | -122 | -121 | N/A |
| 3/31/2019 | N/A | -154 | -127 | -127 | N/A |
| 12/31/2018 | N/A | -155 | -119 | -118 | N/A |
| 9/30/2018 | 0 | -145 | -115 | -114 | N/A |
| 6/30/2018 | 0 | -126 | -101 | -100 | N/A |
| 3/31/2018 | 0 | -106 | -92 | -91 | N/A |
| 12/31/2017 | 0 | -98 | -81 | -80 | N/A |
| 9/30/2017 | 0 | -95 | -84 | -84 | N/A |
| 6/30/2017 | 0 | -102 | -100 | -99 | N/A |
| 3/31/2017 | 0 | -116 | N/A | -88 | N/A |
| 12/31/2016 | 0 | -116 | N/A | -91 | N/A |
| 9/30/2016 | 0 | -118 | N/A | -98 | N/A |
| 6/30/2016 | 0 | -120 | N/A | -89 | N/A |
| 3/31/2016 | 0 | -110 | N/A | -106 | N/A |
| 12/31/2015 | 0 | -105 | N/A | -102 | N/A |
| 9/30/2015 | 0 | -91 | N/A | -73 | N/A |
| 6/30/2015 | 0 | -65 | N/A | -57 | N/A |
| 3/31/2015 | 0 | -48 | N/A | -32 | N/A |
| 12/31/2014 | 1 | -31 | N/A | -23 | N/A |
| 9/30/2014 | 1 | -24 | N/A | -25 | N/A |
| 6/30/2014 | 2 | -22 | N/A | -26 | N/A |
| 3/31/2014 | 2 | -26 | N/A | -27 | N/A |
| 12/31/2013 | 3 | -27 | N/A | -23 | N/A |
| 9/30/2013 | 3 | -20 | N/A | -18 | N/A |
| 6/30/2013 | 2 | -17 | N/A | -19 | N/A |
| 3/31/2013 | 3 | -15 | N/A | -17 | N/A |
| 12/31/2012 | 3 | -17 | N/A | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: I2TC34 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (9.7%).
Earnings vs Market: I2TC34 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: I2TC34 is expected to become profitable in the next 3 years.
Revenue vs Market: I2TC34's revenue (33.2% per year) is forecast to grow faster than the BR market (6.3% per year).
High Growth Revenue: I2TC34's revenue (33.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if I2TC34's Return on Equity is forecast to be high in 3 years time